A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Lebrikizumab (Primary) ; Pirfenidone
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 16 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 25 Oct 2017 This study has been completed in Spain as per European Clinical Trials Database.
    • 20 Jul 2017 Planned End Date changed from 14 Nov 2017 to 15 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top